Seralutinib Update: U.S. Approval Filing Planned
Back in March, we noted that Gossamer Bio’s phase 3 clinical trial of seralutinib (a drug for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease) didn’t meet its primary endpoint, causing a steep drop in its stock price. The study had some promising results: it showed a potentially good response to seralutinib, but some locations had an unusually good response to the placebo, which may have affected the analysis. Despite the study's technical failure, Gossamer Bio said it would explore a path forward for seralutinib in the U.S.
Subsequent months involved corporate machinations and meetings with the U.S. Food and Drug Agency.
On July 27, Gossamer Bio announced it had acquired the rights to develop seralutinib from its partner and planned to submit a New Drug Application (NDA) in the U.S. for seralutinib in September 2026. The FDA could approve seralutinib as early as the 3rd quarter of 2027.
At this point, they have not mentioned any plans to submit seralutinib for approval in Canada.
If your audience has to hunt for your shop, newsletter, or latest video, a multi-link profile setup solves that by putting everything behind one address. It is a practical way to keep your bio from becoming a wall of separate URLs.
A LinkedIn bio works differently from a social media bio because it has to satisfy recruiters and clients at the same time. Breaking the writing process into steps, with frameworks and examples, makes it easier to translate experience into a clear personal brand statement. Biovelt's walkthrough is a sensible starting point: Biovelt's LinkedIn guide.
It's encouraging to see Gossamer Bio moving forward with the NDA for seralutinib despite the trial's mixed results—pulmonary hypertension patients need more treatment options. The FDA's upcoming review could be a pivotal moment. On a related note, tracking complex medical data often requires clear visual tools, something I’ve found helpful when organizing health metrics using well-designed reference charts like those on ChartsPrintables.
This is an interesting update, and I hope future research brings more treatment options for people living with pulmonary hypertension. It’s good to see progress being followed closely. On a different note, classic fashion looks like the hugh hefner costume remain recognizable in pop culture.
When I need a clean slate to dump temporary thoughts, I usually open up Bata because it loads instantly without any clutter.